Marek Hartleb1, Kamil Barański2, Jan Zejda2, Jerzy Chudek3, Andrzej Więcek4. 1. Department of Gastroenterology and Hepatology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. 2. Department of Epidemiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. 3. Department of Pathophysiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. 4. Department of Nephrology, Transplantology and Internal Diseases, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Abstract
BACKGROUND & AIMS: Development of non-alcoholic fatty liver (NAFL) is dependent on metabolic factors occurring at an increased frequency with advancing age. Until now, few studies have explored the prevalence of NAFL in aged populations. Our study aimed to determine the prevalence of NAFL and advanced fibrosis in the elderly population participating in a national survey of a community-based elderly cohort. METHODS: A total of 3003 participants (mean age 79.6 years, 46.8% male) were enrolled in the study, after applying the following exclusion criteria: individuals younger than 65 years old (n=829) and those with positive serological biomarkers of HBV or HCV infection (n=391), chronic alcohol ingestion (n=727) or incomplete data records (n=745). Based on the fatty liver index (FLI), the participants were classified into three categories: FLI<30 (no NAFL), 30≤FLI<60 (borderline) and FLI≥60 (NAFL). According to the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS), the participants were divided into three advanced fibrosis risk categories: NFS<-1.455 (low risk), -1.455≤NFS≤0.676 (intermediate risk) and NFS>0.676 (high risk). RESULTS: The prevalence of NAFL in the general population was 37.2%; the prevalence reached 51.4% in participants 65-70 years of age and decreased with advancing age (P<.0001). The prevalence of advanced fibrosis was 7.79% (14.8% in the NAFL population) and increased with advancing age (P<.005). CONCLUSIONS: The prevalence of NAFL and metabolically driven advanced fibrosis are relatively common in the elderly population, and these hepatic conditions run in adverse directions with advancing age.
BACKGROUND & AIMS: Development of non-alcoholic fatty liver (NAFL) is dependent on metabolic factors occurring at an increased frequency with advancing age. Until now, few studies have explored the prevalence of NAFL in aged populations. Our study aimed to determine the prevalence of NAFL and advanced fibrosis in the elderly population participating in a national survey of a community-based elderly cohort. METHODS: A total of 3003 participants (mean age 79.6 years, 46.8% male) were enrolled in the study, after applying the following exclusion criteria: individuals younger than 65 years old (n=829) and those with positive serological biomarkers of HBV or HCV infection (n=391), chronic alcohol ingestion (n=727) or incomplete data records (n=745). Based on the fatty liver index (FLI), the participants were classified into three categories: FLI<30 (no NAFL), 30≤FLI<60 (borderline) and FLI≥60 (NAFL). According to the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS), the participants were divided into three advanced fibrosis risk categories: NFS<-1.455 (low risk), -1.455≤NFS≤0.676 (intermediate risk) and NFS>0.676 (high risk). RESULTS: The prevalence of NAFL in the general population was 37.2%; the prevalence reached 51.4% in participants 65-70 years of age and decreased with advancing age (P<.0001). The prevalence of advanced fibrosis was 7.79% (14.8% in the NAFL population) and increased with advancing age (P<.005). CONCLUSIONS: The prevalence of NAFL and metabolically driven advanced fibrosis are relatively common in the elderly population, and these hepatic conditions run in adverse directions with advancing age.
Authors: Irena Ciećko-Michalska; Małgorzata Szczepanek; Iga Wierzbicka-Tutka; Janina Zahradnik-Bilska; Tomasz Mach Journal: Arch Med Sci Atheroscler Dis Date: 2018-12-28
Authors: Gloria Alvarez-Sola; Iker Uriarte; Maria U Latasa; Maddalen Jimenez; Marina Barcena-Varela; Eva Santamaría; Raquel Urtasun; Carlos Rodriguez-Ortigosa; Jesús Prieto; Fernando J Corrales; Anna Baulies; Carmen García-Ruiz; Jose C Fernandez-Checa; Pedro Berraondo; Maite G Fernandez-Barrena; Carmen Berasain; Matías A Avila Journal: Cell Death Dis Date: 2017-10-05 Impact factor: 8.469
Authors: Olubunmi O Olubamwo; Jyrki K Virtanen; Jussi Pihlajamaki; Pekka Mantyselka; Tomi-Pekka Tuomainen Journal: BMJ Open Date: 2019-09-05 Impact factor: 2.692